ZA200709091B - Erythropoietin variants - Google Patents

Erythropoietin variants

Info

Publication number
ZA200709091B
ZA200709091B ZA200709091A ZA200709091A ZA200709091B ZA 200709091 B ZA200709091 B ZA 200709091B ZA 200709091 A ZA200709091 A ZA 200709091A ZA 200709091 A ZA200709091 A ZA 200709091A ZA 200709091 B ZA200709091 B ZA 200709091B
Authority
ZA
South Africa
Prior art keywords
erythropoietin variants
erythropoietin
variants
Prior art date
Application number
ZA200709091A
Other languages
English (en)
Inventor
Meisel Andreas
Priller Josef
Bonnas Christel
Dirnagl Ulrich
Original Assignee
Charite Universitaetsmedizin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Charite Universitaetsmedizin filed Critical Charite Universitaetsmedizin
Publication of ZA200709091B publication Critical patent/ZA200709091B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Cardiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ZA200709091A 2005-05-13 2007-10-22 Erythropoietin variants ZA200709091B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05010473A EP1736481A1 (en) 2005-05-13 2005-05-13 Erythropoietin variants

Publications (1)

Publication Number Publication Date
ZA200709091B true ZA200709091B (en) 2009-08-26

Family

ID=36753959

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200709091A ZA200709091B (en) 2005-05-13 2007-10-22 Erythropoietin variants

Country Status (12)

Country Link
EP (2) EP1736481A1 (enExample)
JP (1) JP5231214B2 (enExample)
KR (1) KR101468737B1 (enExample)
CN (1) CN101175768B (enExample)
AU (1) AU2006245916B2 (enExample)
BR (1) BRPI0608769A2 (enExample)
CA (1) CA2608379C (enExample)
DK (1) DK1885747T3 (enExample)
ES (1) ES2457398T3 (enExample)
RU (1) RU2430162C2 (enExample)
WO (1) WO2006120030A1 (enExample)
ZA (1) ZA200709091B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2371855E (pt) 2005-08-05 2015-11-03 Araim Pharmaceuticals Inc Péptidos protetores de tecidos e suas utilizações
WO2008137636A2 (en) * 2007-05-02 2008-11-13 University Of Utah Research Foundation Compositions and methods for identifying and treating subjects at risk of developing type 2 diabetes
DE102007031708A1 (de) 2007-07-06 2009-01-08 Dade Behring Marburg Gmbh Bestimmung der von Willebrand Faktor-Aktivität in Abwesenheit von Ristocetin
SG10201604530SA (en) 2008-01-22 2016-07-28 Araim Pharmaceuticals Inc Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
BR112014007029A2 (pt) 2011-09-23 2017-04-11 Bluebird Bio Inc métodos aperfeiçoados de terapia gênica
KR101148191B1 (ko) * 2011-09-27 2012-05-23 김후정 에리스로포이에틴-유래 펩타이드 및 그 용도
HRP20210517T1 (hr) 2012-12-05 2021-05-14 Novartis Ag Pripravci i postupci za protutijela usmjerena na epo
CN107260760B (zh) * 2013-02-06 2021-08-31 Nc医学研究公司 用于治疗神经变性的细胞疗法
JP2018525389A (ja) 2015-08-12 2018-09-06 ノバルティス アーゲー 眼障害を治療する方法
US11117942B2 (en) 2015-08-31 2021-09-14 The Trustees Of The University Of Pennsylvania AAV-EPO for treating companion animals
KR101965814B1 (ko) * 2017-02-27 2019-08-13 재단법인 대구경북과학기술원 에리스로포이에틴 유래 펩티드의 세포손상방지에 효과를 통한 활용
CN107880109B (zh) * 2017-11-01 2019-08-30 复旦大学附属中山医院 一种促红细胞生成素来源肽及其制备方法和用途
AR113091A1 (es) 2018-09-27 2020-01-22 Univ Nacional Del Litoral Eritropoyetina humana modificada
US11566056B2 (en) 2020-05-26 2023-01-31 Sylus Co., Ltd Peptide and use thereof for treatment of disease of brain and nervous system
CN113376186B (zh) * 2021-05-12 2022-12-23 无锡科金生物科技有限公司 一种精准度高的智能红细胞叶酸检测仪及其检测方法
US20250333489A1 (en) * 2021-06-15 2025-10-30 Andremacon S.R.L. Epo variants and modulators

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4558006A (en) * 1983-02-04 1985-12-10 Kirin-Amgen, Inc. A.T.C.C. HB8209 and its monoclonal antibody to erythropoietin
DE3924746A1 (de) * 1989-07-26 1991-01-31 Behringwerke Ag Erythropoietin (epo)-peptide und dagegen gerichtete antikoerper
ZA946122B (en) 1993-08-17 1995-03-20 Amgen Inc Erythropoietin analogs
US6271196B1 (en) * 1996-03-05 2001-08-07 Regents Of The University Of Ca Methods of alleviating neuropathic pain using prosaposin-derived peptides
DE19857609A1 (de) 1998-12-14 2000-06-15 Hannelore Ehrenreich Verwendung von Erythropoietin zur Behandlung von cerebralen Ischämien des Menschen
US7259146B2 (en) 2000-05-26 2007-08-21 Ortho-Mcneil Pharmaceutical, Inc. Neuroprotective peptides
DE10043457A1 (de) 2000-09-04 2002-03-28 Hannelore Ehrenreich Verfahren zur Behandlung von Schizophrenie und verwandten Psychosen sowie Verwendung von Erythropoietin oder Erythropoietinderivaten zur Behandlung von Schizophrenien und verwandten Psychosen
US6531121B2 (en) 2000-12-29 2003-03-11 The Kenneth S. Warren Institute, Inc. Protection and enhancement of erythropoietin-responsive cells, tissues and organs
CA2491567A1 (en) * 2002-07-01 2004-01-08 The Kenneth S. Warren Institute, Inc. Recombinant tissue protective cytokines and encoding nucleic acids thereof for protection, restoration, and enhancement of responsive cells, tissues, and organs
US20040091961A1 (en) * 2002-11-08 2004-05-13 Evans Glen A. Enhanced variants of erythropoietin and methods of use
CN1882355A (zh) 2003-09-09 2006-12-20 沃伦药品公司 保持内源性促红细胞生成素组织保护活性的长效促红细胞生成素
AU2005235794A1 (en) * 2004-04-23 2005-11-03 Cambridge Antibody Technology Limited Erythropoietin protein variants

Also Published As

Publication number Publication date
JP5231214B2 (ja) 2013-07-10
CN101175768A (zh) 2008-05-07
BRPI0608769A2 (pt) 2010-01-26
WO2006120030A1 (en) 2006-11-16
RU2430162C2 (ru) 2011-09-27
AU2006245916A1 (en) 2006-11-16
ES2457398T3 (es) 2014-04-25
AU2006245916B2 (en) 2012-03-15
EP1885747A1 (en) 2008-02-13
CA2608379A1 (en) 2006-11-16
CN101175768B (zh) 2013-09-11
EP1736481A1 (en) 2006-12-27
KR101468737B1 (ko) 2014-12-09
JP2008539745A (ja) 2008-11-20
EP1885747B1 (en) 2013-11-20
KR20080021595A (ko) 2008-03-07
DK1885747T3 (en) 2014-02-24
WO2006120030A8 (en) 2006-12-28
CA2608379C (en) 2014-12-16
RU2007146455A (ru) 2009-06-20

Similar Documents

Publication Publication Date Title
ZA200709091B (en) Erythropoietin variants
DE502006001600D1 (en) Pyrazolylcarboxanilide
DE602006017073D1 (en) Aspartylproteasehemmer
EP1871379A4 (en) CYANOARYLAMINE
IL232923A0 (en) Enhanced erythropoietin
EP1871655A4 (en) TRIGGER OPERATION FOR SIDE DRIVE
EP1865780A4 (en) MINI OVEN
DE602006015303D1 (en) Lecknachweisflicken
GB0516189D0 (en) U-watch
GB0521981D0 (en) Weedsaway
GB0523623D0 (en) Ezi-wheels
AU3685P (en) DOW10 Tristaniopsis laurina
GB0516150D0 (en) Improved smpsogi
GR1007111B (en) Assembled ballot-box
PH32005001158S1 (en) Sidespray
GB0507414D0 (en) Drydam
GB0500322D0 (en) Slide-in-plate
GB0501782D0 (en) Quick-patch
GB0505226D0 (en) Over-sealing
GB0500013D0 (en) Diallerguard
GB0503390D0 (en) Foldio-addon
AU316720S (en) Swimwear - top
GB0522914D0 (en) Fukboard
GB0522443D0 (en) Aqua-ducting
GB0511038D0 (en) Carapil